The purpose of this proposal is to continue our study of the regulation of tissue kallikrein activity, synthesis and gene expression using both protein chemistry and nucleic acid approaches. Our recent discoveries of kallikrein distribution in new tissue sites and a kallikrein multigene family raises the exciting possibility that kallikrein(s) may play a general role in processing many important precursor proteins into bioactive peptides in addition to kinin formation. Our working hypothesis is that kallikrein gene expression is tissue-specific and differentially regulated by hormones or other physiological factors. Kallikrein may be further regulated posttranslationally by a newly discovered kallikrein binding protein (kallistatin). These findings and our recent development of specific reagents that include pure kallikrein, monoclonal antibodies to kallikrein, kininogen, kinin, kallikrein cDNA, oligonucleotides and kallikrein genomic clones will be used to elucidate the regulation and function of kallikreins. The objective is facilitated by our recent finding of kallikrein induction in estrogen-treated rat pituitary and identification of the synthesis and secretion of kallikrein from a peptide hormone-producing pituitary cell line. The studies will be initiated by purification, characterization and development of monoclonal or polyclonal antibodies to the kallikrein system components (kallikrein, kallistatin, kininogen). These antibodies will be used for quantitation, identification and isolation of the kallikrein components in rat pituitary or pituitary cell lines. Co-localization of the components in the specific cell types of rat pituitary will be determined by immunohistochemistry and/or by cDNA-mRNA in situ hybridization. The regulatory aspects of kallikrein gene expression and enzyme activity will be elucidated using whole animals in vivo and using rat pituitary cell cultures as a model system in vitro. The pathophysiological role of kallikrein will be explored by characterizing kallikrein gene structure, organization and expression in normal and eventually, in hypertensive animal models. The proposal is designed to advance basic knowledge of the function and regulation of tissue kallikrein(s) and their products as the crucial requirement for understanding the role of these enzymes in such disorders as human hypertensive or diabetic disease.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL029397-05
Application #
3340509
Study Section
Biochemistry Study Section (BIO)
Project Start
1986-07-01
Project End
1991-06-30
Budget Start
1987-07-01
Budget End
1988-06-30
Support Year
5
Fiscal Year
1987
Total Cost
Indirect Cost
Name
Medical University of South Carolina
Department
Type
School of Medicine & Dentistry
DUNS #
183710748
City
Charleston
State
SC
Country
United States
Zip Code
29425
Li, Pengfei; Guo, Youming; Bledsoe, Grant et al. (2015) Kallistatin treatment attenuates lethality and organ injury in mouse models of established sepsis. Crit Care 19:200
Chao, Julie; Bledsoe, Grant; Chao, Lee (2014) Tissue kallikrein-kinin therapy in hypertension and organ damage. Prog Drug Res 69:37-57
Gao, Lin; Li, Pengfei; Zhang, Jingmei et al. (2014) Novel role of kallistatin in vascular repair by promoting mobility, viability, and function of endothelial progenitor cells. J Am Heart Assoc 3:e001194
Li, Pengfei; Bledsoe, Grant; Yang, Zhi-Rong et al. (2014) Human kallistatin administration reduces organ injury and improves survival in a mouse model of polymicrobial sepsis. Immunology 142:216-26
Zhang, Jingmei; Yang, Zhirong; Li, Pengfei et al. (2013) Kallistatin antagonizes Wnt/*-catenin signaling and cancer cell motility via binding to low-density lipoprotein receptor-related protein 6. Mol Cell Biochem 379:295-301
Yao, Yuyu; Sheng, Zulong; Li, YeFei et al. (2013) Tissue kallikrein-modified human endothelial progenitor cell implantation improves cardiac function via enhanced activation of akt and increased angiogenesis. Lab Invest 93:577-91
Gao, Lin; Bledsoe, Grant; Yin, Hang et al. (2013) Tissue kallikrein-modified mesenchymal stem cells provide enhanced protection against ischemic cardiac injury after myocardial infarction. Circ J 77:2134-44
Zhou, J; Zhang, J; Chao, J (2012) Porphyromonas gingivalis promotes monocyte migration by activating MMP-9. J Periodontal Res 47:236-42
Liu, Yuying; Bledsoe, Grant; Hagiwara, Makato et al. (2012) Depletion of endogenous kallistatin exacerbates renal and cardiovascular oxidative stress, inflammation, and organ remodeling. Am J Physiol Renal Physiol 303:F1230-8
Liu, Yuying; Bledsoe, Grant; Hagiwara, Makato et al. (2010) Blockade of endogenous tissue kallikrein aggravates renal injury by enhancing oxidative stress and inhibiting matrix degradation. Am J Physiol Renal Physiol 298:F1033-40

Showing the most recent 10 out of 187 publications